Close Menu

NEW YORK (360Dx) – Chembio Diagnostics said after the close of the market on Thursday that its fourth quarter revenues grew 40 percent year over year.

For the three months ended Dec. 31, 2017, the company posted total revenues of $6.0 million, up from $4.3 million in the year-ago period. Product sales rose to $4.9 million from $3.2 million; licensing and royalty revenues were down to $263,902 from $315,835; and R&D, milestones and grant revenues increased to $854,965 from $712,122.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.